Noteworthily, following 6 months of adalimumab therapy, a statistically negative correlation between TBS values and insulin resistance (measured by HOMA; r = −0.445; p = 0.02) and a positive one between TBS and insulin sensitivity (QUICKI; r = 0.497; p = 0.01) were found. Here, INS is linked to Insulin resistance.